JHVEPhoto Barron’s said this week that ResMed (NYSE:RMD) trades at a compelling valuation after the stock sold off last month in reaction to positive data for Eli Lilly’s (NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep apnea, a condition targeted by the MedTech company. In late June, Lilly (LLY) said tirzepatide,Continue Reading
Pgiam/iStock via Getty Images Oppenheimer downgraded respiratory device maker ResMed (NYSE:RMD) to Perform from Outperform on Tuesday, citing an “air pocket” for the stock in the wake of encouraging data for Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide in obstructive sleep apnea (OSA). The maker of CPAP (continuous positive airwayContinue Reading
JHVEPhoto Inspire Medical Systems (NYSE:INSP) and ResMed (NYSE:RMD) are both down significantly in Monday trading, apparent casualties of positive data released after the closing bell on June 21 of Eli Lilly’s (LLY) diabetes and weight loss drug tirzepatide as a sleep apnea treatment. Inspire manufactures an implantable neurostimulation device forContinue Reading
jetcityimage/iStock Editorial via Getty Images Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy tirzepatide against obstructive sleep apnea (OSA) is expected later this year. The announcement hurt theContinue Reading
